Skip to main content
HBIO
NASDAQ Industrial Applications And Services

Harvard Bioscience Q3 Revenue Up 8% to $22.2M; Full-Year EBITDA Guidance Cut

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$9.09
Mkt Cap
$41.38M
52W Low
$4
52W High
$9.32
52W Position info
127% above low
Off High info
2.5% below high
Rel. Volume info
2.3× avg
Market data snapshot near publication time

HBIO has more than doubled off its 52-week low of $4 on elevated volume (2.3× avg).

Summary

Harvard Bioscience grew Q3 revenue 8% to $22.2M but gross margin compressed to 55.4% and full-year adjusted EBITDA guidance was cut to (1%)-4% growth. The net loss widened to $2.6M and cash fell to $4.9M against $37.2M of debt.


Key Events · Earnings and Guidance · HBIO

  • Q3 Revenue Grows 8% to $22.2M

    Third-quarter 2026 revenue was $22.2 million versus $20.6 million a year earlier, with double-digit growth to CROs and China customers in organoids, respiratory and fluidics products.

  • Gross Margin Compresses to 55.4%

    GAAP gross margin fell from 58.4% to 55.4% and adjusted gross margin from 59.2% to 57.1%, driven by higher sales of lower-margin CMT products and greater distribution and China contribution.

  • Full-Year EBITDA Guidance Cut

    Full-year 2026 adjusted EBITDA is now expected at (1%) to 4% growth, while revenue growth guidance of 3%-5% and adjusted gross margin of 57%-59% were reaffirmed.

  • Net Loss Widens, Cash Burn Returns

    Q3 net loss was $2.6 million versus $1.2 million a year ago; interest expense rose to $1.8 million from $1.3 million and operating cash flow was $(0.2) million versus $1.0 million.


Analysis · HBIO · Industrial Applications And Services

Revenue growth is real — $22.2M in Q3 versus $20.6M a year ago — but the quality of that growth is deteriorating. Gross margin fell to 55.4% from 58.4% as lower-margin CMT products and distribution/China sales took a bigger share of the mix, and the company now expects full-year adjusted EBITDA of (1%) to 4% growth instead of prior expectations. Net loss widened to $2.6M from $1.2M, interest expense rose to $1.8M from $1.3M, and operations burned $0.2M of cash in the quarter versus generating $1.0M a year ago. With $4.9M of cash against $37.2M of debt, the reaffirmed revenue guide matters less than the margin and cash trajectory.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HBIO was trading at $9.09 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $41.4M. The 52-week trading range was $4.00 to $9.32. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HBIO - Latest Insights

HBIO
Nov 10, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.09
Real-time Price: $9.09 info
Change: $0 (0%) info
Market Cap: $41.38M info
HBIO
Nov 10, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $9.09
Real-time Price: $9.09 info
Change: $0 (0%) info
Market Cap: $41.38M info
HBIO
Aug 11, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.13
Real-time Price: $9.09 info
Change: +$2.96 (+48%) info
Market Cap: $41.38M info
HBIO
Aug 11, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.41
Real-time Price: $9.09 info
Change: +$2.68 (+42%) info
Market Cap: $41.38M info
HBIO
Jun 02, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.46
Real-time Price: $9.09 info
Change: +$2.63 (+41%) info
Market Cap: $41.38M info